Australia markets closed
  • ALL ORDS

    7,320.70
    +8.70 (+0.12%)
     
  • ASX 200

    7,060.70
    +5.30 (+0.08%)
     
  • AUD/USD

    0.7745
    +0.0038 (+0.49%)
     
  • OIL

    62.25
    +0.82 (+1.33%)
     
  • GOLD

    1,774.20
    -7.80 (-0.44%)
     
  • BTC-AUD

    63,866.15
    -7,900.33 (-11.01%)
     
  • CMC Crypto 200

    1,134.69
    +10.79 (+0.96%)
     
  • AUD/EUR

    0.6415
    +0.0007 (+0.11%)
     
  • AUD/NZD

    1.0777
    +0.0021 (+0.20%)
     
  • NZX 50

    12,650.64
    +73.16 (+0.58%)
     
  • NASDAQ

    13,852.27
    +89.91 (+0.65%)
     
  • FTSE

    6,917.39
    -20.85 (-0.30%)
     
  • Dow Jones

    33,933.74
    +117.84 (+0.35%)
     
  • DAX

    15,226.27
    -94.25 (-0.62%)
     
  • Hang Seng

    29,078.75
    +323.41 (+1.12%)
     
  • NIKKEI 225

    29,020.63
    -167.54 (-0.57%)
     

UNITY Biotechnology Reports Granting of New Employment Inducement Awards

Unity Biotechnology, Inc.
·1-min read

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that from February 9, 2021 through February 23, 2021, the Board of Directors (the “Board”) granted 5 new employees stock-based awards covering an aggregate of 19,000 shares of UNITY common stock, including options to purchase an aggregate of 19,000 shares of UNITY common stock. The stock-based awards were granted pursuant to the UNITY 2020 Employment Inducement Incentive Plan, as amended, which was approved by the Board in March 2020 to provide for grants to newly hired employees as a material inducement for them to commence employment with UNITY in accordance with Nasdaq Stock Market Rule 5635(c)(4).

About UNITY
UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.

CONTACT: Media Canale Communications Jason Spark Jason.spark@canalecomm.com